Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202
Debt
Debt-to-Equity RatioN/A
Current Ratio4.00
Quick Ratio4.00
Price-To-Earnings
Trailing P/E Ratio-12.22
Forward P/E Ratio-11.04
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.21 million
Price / Sales42.00
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book10.02
Profitability
EPS (Most Recent Fiscal Year)($2.24)
Net Income$-109,750,000.00
Net Margins-192.97%
Return on Equity-58.32%
Return on Assets-39.38%
Miscellaneous
Employees100
Outstanding Shares85,720,000
Market Cap$2.07 billion
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Monday, August, 6th. The company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.04) by $0.32. The company earned $18.30 million during the quarter, compared to the consensus estimate of $14.24 million. Akcea Therapeutics had a negative net margin of 192.97% and a negative return on equity of 58.32%. Akcea Therapeutics's revenue was up 221.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.41) earnings per share. View Akcea Therapeutics' Earnings History.
What price target have analysts set for AKCA?
6 Wall Street analysts have issued 1-year target prices for Akcea Therapeutics' shares. Their forecasts range from $25.00 to $46.00. On average, they expect Akcea Therapeutics' share price to reach $39.00 in the next year. This suggests a possible upside of 44.2% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE) and Agios Pharmaceuticals (AGIO).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 50)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
- Ms. Sarah Boyce, Pres & Director (Age 46)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.
Has Akcea Therapeutics been receiving favorable news coverage?
News coverage about AKCA stock has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a news impact score of 0.18 on Accern's scale. They also gave news headlines about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Akcea Therapeutics.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.53%), BB Biotech AG (2.90%), BlackRock Inc. (2.22%), Bellevue Group AG (0.44%), Northern Trust Corp (0.21%) and Alps Advisors Inc. (0.14%). View Institutional Ownership Trends for Akcea Therapeutics.
Which institutional investors are selling Akcea Therapeutics stock?
Which institutional investors are buying Akcea Therapeutics stock?
AKCA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Bellevue Group AG, Alps Advisors Inc., BlackRock Inc., BB Biotech AG, Millennium Management LLC, Northern Trust Corp and Strs Ohio. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $27.05.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $2.07 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
